CoChat
Sign Up
Cited by 7

The DOI matches its Crossref record.

Matrix metalloproteinase inhibitor Ro 28-2653 in combination with estramustine: tumor-reducing effects on hormone-sensitive prostate cancer in rats

Abramjuk, Claudia, Jung, Klaus, Krell, Hans-Willi, Juchem, Rolf, Peters, Robert, Taymoorian, Kasra, Staack, Andrea, Stephan, Carsten, Schnorr, Joerg, Loening, Stefan A., Lein, Michael·2005·Anti-Cancer Drugs
DOI 10.1097/01.cad.0000173477.05358.ec
Open this paper in CoChat — free account

Abstract

Therapeutic efficacy of the novel matrix metalloproteinase (MMP) inhibitor, Ro 28-2653 (5-biphenyl-4-yl-5-[4-(-nitro-phenyl)-piperazin-1-yl]-pyrimidine-2,4,6-trione), has been shown in various models of different tumor entities. The tumor growth-reducing effect has been demonstrated in the orthotopic rat prostate Dunning model (subline MatLyLu). Based on these results we investigated Ro 28-2653 in combination with estramustine on the G subline of the Dunning tumor. This subline is characterized by a low metastatic ability and androgen sensitivity. Efficacy was determined by recording tumor growth in vivo by magnetic resonance imaging (MRI). Tumor cells were injected into the prostates of 81 Copenhagen rats. MRI was performed at day 100 and at day 126 after tumor cell injection. The duration of therapy was 17 days with daily oral application of Ro 28-2653 (100 mg/kg) and four i.p. injections of estramustine (7.5 mg/kg). Histological evaluations were conducted to provide further information about the effects on tumor morphology. Orthotopic tumor induction was successful in 100% of the animals. Tumor volume calculations with MRI showed a significant difference between the control groups, the animals treated with Ro 28-2653, and the animals treated with the combination of Ro 28-2653 and estramustine. The new MMP inhibitor Ro 28-2653 reduces tumor growth and provides a compatible therapeutic alternative for patients with prostate cancer.

Overview

Integrity signals

Registry

Crossref · 10.1097/01.cad.0000173477.05358.ec

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • As a hydroxamic acid-based MMP inhibitor, Ro 28-2653 may also display lower binding affinity for other MMPs, as well as for ADAM and ADAMTS metalloproteinases.

    “As a hydroxamic acid-based MMP inhibitor, it may also display lower binding affinity for other MMPs, as well as for ADAM and A Disintegrin and Metalloproteinase with Thrombospondin Motifs (ADAMTS) metalloproteinases31–35.”

    From MT1-MMP inhibition rejuvenates ageing brain and rescues cognitive deficits in obesity (2025) · cites this paper as [31]

  • Ro 28-2653 is an orally available, brain-penetrant inhibitor with high specificity for MT1-MMP, MMP2, and MMP9.

    “Ro 28-2653 is an orally available, brain-penetrant inhibitor with high specificity for MT1-MMP, MMP2, and MMP9.”

    From MT1-MMP inhibition rejuvenates ageing brain and rescues cognitive deficits in obesity (2025) · cites this paper as [31]

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 36

  1. Jemal, 2005, Cancer statistics, 2005, CA Cancer J Clin, 55, 10, 10.3322/canjclin.55.1.10 · DOI · Paper page
  2. Pirtskhalaishvili, 2001, The treatment of prostate cancer: an overview of current options, Cancer Pract, 9, 295, 10.1046/j.1523-5394.2001.96009.x · DOI
  3. Klein, 2003, Localized prostate cancer: radiation or surgery?, Urol Clin North Am, 30, 315, 10.1016/S0094-0143(02)00179-9 · DOI
  4. Jenster, 1999, The role of the androgen receptor in the development and progression of prostate cancer, Semin Oncol, 26, 407
  5. Martel, 2003, Current strategies in the management of hormone refractory prostate cancer, Cancer Treat Rev, 29, 171, 10.1016/S0305-7372(02)00090-7 · DOI
  6. Lucia, 1998, Workgroup I: rodent models of prostate cancer, Prostate, 36, 49, 10.1002/(SICI)1097-0045(19980615)36:1<49::AID-PROS9>3.0.CO;2-6 · DOI
  7. Lubaroff, 1980, The Dunning tumors, Prog Clin Biol Res, 37, 243
  8. Lein, 2002, The new synthetic matrix metalloproteinase inhibitor (Roche 28-2653) reduces tumor growth and prolongs survival in a prostate cancer standard rat model, Oncogene, 21, 2089, 10.1038/sj.onc.1205267 · DOI
  9. Mangoldt, 2002, The novel synthetic inhibitor of matrix metalloproteinases Ro 28-2653 induces apoptosis in Dunning tumor cells, Apoptosis, 7, 217, 10.1023/A:1015383231080 · DOI
  10. Jung, 2003, Plasma matrix metalloproteinase 9 as biomarker of prostate cancer progression in Dunning (Copenhagen) rats, Prostate, 54, 206, 10.1002/pros.10183 · DOI
  11. Maquoi, 2004, Antiinvasive, antitumoral, and antiangiogenic efficacy of a pyrimidine-2,4,6-trione derivative, an orally active and selective matrix metalloproteinases inhibitor, Clin Cancer Res, 10, 4038, 10.1158/1078-0432.CCR-04-0125 · DOI
  12. Liotta, 1991, Tumor invasion and metastasis: an imbalance of positive and negative regulation, Cancer Res, 51, 5054s
  13. Egeblad, 2002, New functions for the matrix metalloproteinases in cancer progression, Nat Rev Cancer, 2, 161, 10.1038/nrc745 · DOI · Paper page
  14. Overall, 2002, Strategies for MMP inhibition in cancer: innovations for the post-trial era, Nat Rev Cancer, 2, 657, 10.1038/nrc884 · DOI · Paper page
  15. Kahari, 1999, Matrix metalloproteinases and their inhibitors in tumour growth and invasion, Ann Med, 31, 34, 10.3109/07853899909019260 · DOI
  16. Westermarck, 1999, Regulation of matrix metalloproteinase expression in tumor invasion, FASEB J, 13, 781, 10.1096/fasebj.13.8.781 · DOI
  17. Roeb, 2001, Activity and cellular origin of gelatinases in patients with colon and rectal carcinoma differential activity of matrix metalloproteinase-9, Cancer, 92, 2680, 10.1002/1097-0142(20011115)92:10<2680::AID-CNCR1622>3.0.CO;2-7 · DOI
  18. Kanoh, 2002, Expression of matrix metalloproteinase-2 and prostate-specific antigen in localized and metastatic prostate cancer, Anticancer Res, 22, 1813
  19. Hamacher, 2004, [Extracellular matrix—from basic research to clinical significance. An overview with special consideration of matrix metalloproteinases], Dtsch Med Wochenschr, 129, 1976, 10.1055/s-2004-831836 · DOI
  20. Lein, 2000, Synthetic inhibitor of matrix metalloproteinases (batimastat) reduces prostate cancer growth in an orthotopic rat model, Prostate, 43, 77, 10.1002/(SICI)1097-0045(20000501)43:2<77::AID-PROS1>3.0.CO;2-Q · DOI
  21. Isaacs, 1986, Establishment and characterization of seven Dunning rat prostatic cancer cell lines and their use in developing methods for predicting metastatic abilities of prostatic cancers, Prostate, 9, 261, 10.1002/pros.2990090306 · DOI
  22. Oh, 2003, A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813, Cancer, 98, 2592, 10.1002/cncr.11829 · DOI
  23. Albrecht, 2004, Randomized Phase II trial assessing estramustine and vinblastine combination chemotherapy vs estramustine alone in patients with progressive hormone-escaped metastatic prostate cancer, Br J Cancer, 90, 100, 10.1038/sj.bjc.6601468 · DOI
  24. Itoh, 1998, Reduced angiogenesis and tumor progression in gelatinase A-deficient mice, Cancer Res, 58, 1048
  25. Chang, 2001, The many faces of metalloproteases: cell growth, invasion, angiogenesis and metastasis, Trends Cell Biol, 11, S37, 10.1016/S0962-8924(01)02122-5 · DOI
  26. Lambert, 2002, Matrix metalloproteinase-9 contributes to choroidal neovascularization, Am J Pathol, 161, 1247, 10.1016/S0002-9440(10)64401-X · DOI
  27. Wojtowicz-Praga, 1997, Matrix metalloproteinase inhibitors, Invest New Drugs, 15, 61, 10.1023/A:1005722729132 · DOI
  28. Hidalgo, 2001, Development of matrix metalloproteinase inhibitors in cancer therapy, J Natl Cancer Inst, 93, 178, 10.1093/jnci/93.3.178 · DOI
  29. Coussens, 2002, Matrix metalloproteinase inhibitors and cancer: trials and tribulations, Science, 295, 2387, 10.1126/science.1067100 · DOI · Paper page
  30. Fingleton, 2003, Matrix metalloproteinase inhibitors for cancer therapy: the current situation and future prospects, Expert Opin Ther Targets, 7, 385, 10.1517/14728222.7.3.385 · DOI
  31. Pavlaki, 2003, Matrix metalloproteinase inhibitors (MMPIs): the beginning of phase I or the termination of phase III clinical trials, Cancer Metastasis Rev, 22, 177, 10.1023/A:1023047431869 · DOI
  32. Andarawewa, 2003, Dual stromelysin-3 function during natural mouse mammary tumor virus-ras tumor progression, Cancer Res, 63, 5844
  33. Balbin, 2003, Loss of collagenase-2 confers increased skin tumor susceptibility to male mice, Nat Genet, 35, 252, 10.1038/ng1249 · DOI
  34. Folgueras, 2004, Matrix metalloproteinases in cancer: from new functions to improved inhibition strategies, Int J Dev Biol, 48, 411, 10.1387/ijdb.041811af · DOI
  35. Freije, 2003, Matrix metalloproteinases and tumor progression, Adv Exp Med Biol, 532, 91, 10.1007/978-1-4615-0081-0_9 · DOI
  36. Hojilla, 2003, Matrix metalloproteinases and their tissue inhibitors direct cell fate during cancer development, Br J Cancer, 89, 1817, 10.1038/sj.bjc.6601327 · DOI

Cited by

Sorted by citations

Metadata

Authors
Abramjuk, C., Jung, K., Krell, H.-W., Juchem, R., Peters, R., Taymoorian, K., Staack, A., Stephan, C., Schnorr, J., Loening, S. A., & Lein, M.
Venue
Anti-Cancer Drugs
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
2005-09
Volume
16
Issue
8
Pages
855-861
ISSN
0959-4973
DOI
10.1097/01.cad.0000173477.05358.ec
Cited by
7
References
0
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review